Skip to Content

Catabasis Pharmaceuticals Inc CATB

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Catabasis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company focuses on the discovery, development and commercialization of novel therapeutics.It develops products for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. Its product candidate includes QLS-215.

Contact
100 High Street, Floor 28
Boston, MA, 02110
T +1 617 349-1971
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2021
Stock Type Distressed
Employees 20